emperor-preserved-heart-failure-full-data emperor-preserved-heart-failure-full-data Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
empa-reg-outcome-recurrent-events empa-reg-outcome-recurrent-events EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Boehringer Ingelheim good 2021 business performance Boehringer Ingelheim good 2021 business performance 2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Spesolimab Phase II data Spesolimab Phase II data New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Groundbreaking oncology research zongertinib Groundbreaking oncology research zongertinib Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Zongertinib positive results non-small cell lung cancer Zongertinib positive results non-small cell lung cancer Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
EASi-HF™ Phase III trial in patients with HFpEF EASi-HF™ Phase III trial in patients with HFpEF Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
real-world-benefit-shown-in-T2D-treatment real-world-benefit-shown-in-T2D-treatment Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Performance Indicators Performance Indicators Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe
Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results